Epigenetic regulatory mechanisms and therapeutic opportunities in endometriosis

项目摘要 子宫内膜异位症影响每10名育龄妇女中的1名，并与慢性盆腔疼痛和 不孕不育。本病的特点是子宫内膜异常组织出现在子宫内膜以外的部位。 子宫。目前治疗子宫内膜异位症的方法仅限于手术、激素治疗和疼痛。 管理层。对专门针对异常情况的非激素治疗方案的需求尚未得到满足 子宫内膜组织。逆行月经促进子宫内膜组织从子宫扩散到 腹膜腔内的异位部位。尽管逆行月经在月经异常的形成中起着一定作用 这种疾病，额外的因素是子宫内膜异位症发展所必需的。了解如何流离失所 引起这种疾病的子宫内膜细胞需要了解其分子机制 子宫内膜细胞侵袭、存活和异位定植。复发性ARID1A的最新鉴定 子宫内膜异位症病变中的突变支持子宫内膜异位症表观遗传失调的原因 发展。我们假设，表观遗传失调使移位的子宫内膜细胞易于发生 通过促进子宫内膜细胞必需的基因和途径的异常表达而导致的子宫内膜异位症 入侵和生存。在这项研究中，我们将利用创新的模型系统和先进的组学技术 探讨基因组、表观基因组和转录组在子宫内膜异位症发生发展中的作用 新的防治策略。在目标1中，我们将确定组蛋白的机制 乙酰转移酶活性和组蛋白乙酰化促进子宫内膜侵袭和存活。我们将提供 组蛋白乙酰转移酶抑制作为女性潜在的非激素治疗策略的理论基础 患有子宫内膜异位症。在目标2中，我们将讨论变异组蛋白交换在子宫内膜异位症中的作用。 发展。我们的主要目标是揭示导致 子宫内膜异位症和寻找利用杠杆作用靶向异常子宫内膜细胞的新方法 由疾病的表观遗传变化引起的脆弱性。我们的抱负目标是发现新的 明确诊断、预防和治疗子宫内膜异位症的方法。

Project Summary Endometriosis affects 1 in 10 women of reproductive age and is associated with chronic pelvic pain and infertility. The disease is characterized by the presence of abnormal endometrial tissue at sites outside the uterus. Current treatment options for endometriosis are limited to surgery, hormone therapy and pain management. There is an unmet need for non-hormonal treatment options that specifically target abnormal endometrial tissue. Retrograde menstruation promotes the spread of endometrial tissue from the uterus to ectopic sites within the peritoneal cavity. Although retrograde menstruation plays a role in the establishment of the disease, additional factors are necessary for endometriosis development. Understanding how displaced endometrial cells cause the disease requires an understanding of the molecular mechanisms that allow endometrial cells to invade, survive and colonize ectopic sites. The recent identification of recurrent ARID1A mutations in endometriotic lesions supports a causal role for epigenetic dysregulation in endometriosis development. We hypothesize that epigenetic dysregulation predisposes displaced endometrial cells to endometriosis by promoting the aberrant expression of genes and pathways necessary for endometrial cell invasion and survival. In this study, we will utilize innovative model systems and advanced `omics technologies to investigate the role of the genome, epigenome and transcriptome in endometriosis development and inform new prevention and treatment strategies. In Aim 1, we will determine the mechanism by which histone acetyltransferase activity and histone acetylation promotes endometrial invasion and survival. We will provide rationale for histone acetyltransferase inhibition as a potential non-hormonal therapeutic strategy for women with endometriosis. In Aim 2, we will address the role of variant histone exchange in endometriosis development. Our primary objectives are to uncover the epigenetic regulatory mechanisms that lead to endometriosis and find new ways to therapeutically target abnormal endometrial cells by leveraging vulnerabilities that arise from epigenetic alterations in the disease. Our aspirational goals are to identify new ways to definitively diagnose, prevent and treat endometriosis.